STOCK TITAN

Shattuck Labs (STTK) 10-K Filings

STTK NASDAQ

Here are the 10-K annual reports from Shattuck Labs, Inc. (STTK) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow STTK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STTK filings page.

Rhea-AI Summary

Shattuck Labs, Inc. provides an annual business update focused on its DR3/TL1A antibody platform for inflammatory and immune‑mediated diseases. The company’s lead program, SL‑325, is a high‑affinity DR3‑blocking monoclonal antibody in a randomized Phase 1 SAD/MAD trial in healthy volunteers, with enrollment expected to complete in the second quarter of 2026 and a Phase 2 Crohn’s disease trial planned for the third quarter of 2026.

Preclinical GLP studies in non‑human primates showed full, durable DR3 receptor occupancy at doses as low as 1 mg/kg and a no‑observed‑adverse‑effect level at 100 mg/kg, supporting extended dosing intervals. Shattuck is also advancing SL‑425, a half‑life‑extended DR3 antibody, and multiple preclinical DR3‑based bispecific antibodies, while emphasizing intellectual property, outsourced cGMP manufacturing, and detailed compliance with U.S. and international biologics regulations.